Skip to main content
. 2004 Nov 10;24(45):10074–10083. doi: 10.1523/JNEUROSCI.2604-04.2004

Figure 3.

Figure 3.

Double transgenic mice released from doxycycline on E16 develop medulloblastoma. A, Low-power magnification of the brain of a P21 double transgenic mouse released from doxycycline on E16 shows a tumor diffusely involving the molecular layer of the cerebellum with multiple foci of extension to the brainstem. B, Hematoxylin and eosin staining shows normal cerebellum of P21 double transgenic mouse released from doxycycline at birth. C, High-power magnification shows hypercellular tumor consisting of densely packed cells with hyperchromatic nuclei and mitotic activity (arrows). D, Many proliferating cells in the tumor are revealed with BrdU labeling (arrows; green fluorescence), with weak blue fluorescence showing DAPI counterstain. E, Immunostaining shows that many tumor cells are positive for synaptophysin.F, Immunoreactivity for GFAP is mostly confined to cell processes between tumor cells. Scale bars: A, 1000 μm; B, 200 μm; C, E, F, 25 μm; D, 50 μm.